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It has come to our attention that during production of the original article, some of the column headings were missing from Tables 1 and 2. The corrected Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} can be found below. The publisher apologises for any inconvenience caused.Table 1Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents prior to generic availabilityMedicationMonthly cost after deductibleMonthly cost in gapMonthly cost in catastrophicMedian of state mean costsMedian of state mean costsMedian of state mean costs\$, (Range of mean costs)\$, (Range of mean costs)\$, (Range of mean costs)20072010Change (%)20072010Change (%)20072010Change (%)Arimidex39.64 (38.37--48.19)62.83 (60.00--74.75)+58258.64 (247.44--263.47)392.84 (375.66--418.58)+5213.18 (12.68--13.32)19.65 (19.03--20.93)+49Aromasin42.57 (40.72--50.94)86.50 (81.51--101.08)+103267.56 (255.21--273.62)353.98 (351.86--377.07)+3213.66 (13.07--13.79)17.70 (17.59--18.85)+30Femara41.92 (39.38--51.11)89.03 (80.95--102.77)+112277.65 (249.14--282.54)433.42 (430.46--461.42)+5614.16 (12.96--14.34)21.67 (21.55--23.07)+53Tamoxifen6.19 (5.95--9.22)5.98 (5.66--6.75)−321.32 (20.36--25.42)15.52 (15.03--18.90)−272.26 (2.20--2.70)2.60 (2.58--2.75)+15Table 2Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents before and after availability of generic alternativesMedicationMonthly cost after deductibleMonthly cost in gapMonthly cost in catastrophicMedian of state mean costsMedian of state mean costsMedian of state mean costs\$, (Range of mean costs)\$, (Range of mean costs)\$, (Range of mean costs)20072011^a^Change (%)20072011^a^Change (%)20072011^a^Change (%)Arimidex/Anastrozole39.64 (38.37--48.19)9.57 (8.00--11.95)−76258.64 (247.44--263.47)38.94 (31.80--78.46)−8513.18 (12.68--13.32)3.72 (3.39--6.19)−72Aromasin/Exemestane42.57 (40.72--50.94)49.50 (42.34--118.68)+16267.56 (255.21--273.62)244.51 (228.61--270.95)−913.66 (13.07--13.79)14.41 (13.51--71.41)+6Femara/Letrozole41.92 (39.38--51.11)69.31 (59.69--85.17)+65277.65 (249.14--282.54)225.13 (209.10--252.23)−1914.16 (12.96--14.34)38.53 (33.70--57.15)+172Tamoxifen6.19 (5.95--9.22)5.54 (5.12--6.89)−1121.32 (20.36--25.42)13.17 (12.44--21.11)−382.26 (2.20--2.70)2.73 (2.50--3.47)+21^a^First year generic formulation was available to Medicare Part D beneficiaries; generic cost provided

The online version of the original article can be found under doi:10.1186/s40064-015-0827-8.
